| 발표일자: |
2018년 11월 2일(금) ~ 11월 4(일) |
| 발표번호: |
P(e-poster)-174 |
| 발표장소: |
코엑스 컨퍼런스룸 3층 301 A-B |
|
|
| 망막전막 환자에서 백내장 수술시 유리체강내 베바시주맙 주사술 병합의 술후 황반부종에 미치는 효과 |
| 울산대학교 의과대학 서울아산병원 안과학교실 |
| 김승모, 김모세, 이진아, 이창목, 김재용, 김명준, 차흥원 |
|
목적 : Purpose : To evaluate the intraoperative intravitreal Bevacizumab injection in cataract surgery to prevent postoperative macular edema in epiretinal membrane (ERM) patients.
방법 : Methods : This retrospective study included the optical coherence tomography (OCT)-proved ERM patients who underwent phacoemulsification and intraocular lens implantation with a intraoperative 2.5-mg bevacizumab intravitreal injection (6 eyes). Preoperative and postoperative 1 month best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were measured by OCT, and adverse events were recorded.
결과 : Results : At postoperative 1 month, mean BCVA (logMAR) was significantly better than preoperative BCVA (0.11±0.11 vs. 0.33±0.12, postoperative vs. preoperative respectively, p = 0.046) and mean CFT (micrometer) was not changed significantly compared to preoperative CFT (338.33±57.42 vs. 317.67±39.82, postoperative vs. preoperative respectively, p = 0.075). None of the patients experienced injection- or surgery-related complications or any obvious systemic adverse events.
결론 : Conclusions: The short-term results suggest that intraoperative intravitreal bevacizumab injection might be able to prevent postoperative macular edema in ERM patients.
|
| |